EyePoint Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced it will host a conference call on May 4, 2022, at 8:30 a.m. ET to discuss its first quarter 2022 financial results and recent corporate developments. The call can be accessed by dialing (877) 312-7507 for domestic or (631) 813-4828 for international listeners, using conference ID 9257913. Additionally, a live audio webcast will be available on the company’s website, along with a replay post-call.
EyePoint specializes in therapeutics for serious eye disorders, leveraging its Durasert® technology for sustained drug delivery.
- EyePoint has a strong pipeline, including EYP-1901 for wet age-related macular degeneration.
- The Durasert® technology has been safely used in thousands of patients across FDA-approved products.
- None.
WATERTOWN, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 4, 2022 to report its first quarter 2022 financial results and highlight recent corporate developments.
To access the live conference call, please dial (877) 312-7507 (domestic) or (631) 813-4828 (international) and reference conference ID 9257913. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com. A webcast replay will also be available on the corporate website at the conclusion of the call.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert’s proven intravitreal drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
Investors:
Christina Tartaglia
Stern IR
Direct: (212)-698-8700
christina.tartaglia@sternir.com
Media Contact
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
FAQ
When will EyePoint Pharmaceuticals report its Q1 2022 financial results?
How can I access the EyePoint Pharmaceuticals conference call?
What is EyePoint Pharmaceuticals' stock symbol?
What technology does EyePoint Pharmaceuticals use for drug delivery?
